NASDAQ:CMMB Chemomab Therapeutics Q1 2026 Earnings Results & Report $1.53 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$1.54 +0.01 (+0.98%) As of 11/13/2026 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Chemomab Therapeutics missed analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.22 versus the -$0.04 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeBefore Market OpensConference Call8:00 AM ET Chemomab Therapeutics EPS ResultsActual EPS-$0.22Consensus EPS -$0.04Beat/MissMissed by -$0.18One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersChemomab Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Chemomab Therapeutics Q1 2026 Earnings FAQ Did Chemomab Therapeutics beat earnings estimates for Q1 2026? Chemomab Therapeutics (NASDAQ:CMMB) reported earnings of -$0.22 per share for Q1 2026, missing the consensus estimate of -$0.04. The report was announced on Thursday, May 14, 2026. Chemomab Therapeutics Earnings HeadlinesChemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is EffectiveNovember 2, 2026 | globenewswire.comChemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor ConferenceAugust 31, 2026 | globenewswire.comExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it. | Porter & Company (Ad)Chemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 19, 2026 | finanznachrichten.deChemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 19, 2026 | globenewswire.comChemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks TranscriptJuly 8, 2026 | seekingalpha.comSee More Chemomab Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email. Email Address About Chemomab TherapeuticsChemomab Therapeutics (NASDAQ:CMMB) is an Israel-based clinical-stage biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. Its research focuses on CCL24, a signaling protein the company believes contributes to inflammation and tissue scarring. The company’s lead candidate, CM-101, is a monoclonal antibody designed to block CCL24. Chemomab has studied the candidate in conditions including primary sclerosing cholangitis and systemic sclerosis. Chemomab was previously a privately held company and became publicly traded in 2021 through a merger with Anchiano Therapeutics. Its leadership has included co-founder Yuval Cohen as chief executive officer.View Chemomab Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.